University of California San Francisco
Give to UCSF
UCSF Prostate Cancer Survivor Grows a Beard for a Good Cause
<p>For the first time in his life, 50-year-old Art Wagner is growing a beard to raise awareness of prostate cancer after he was successfully treated at UCSF Medical Center. </p>
Rethinking Prostate Cancer with Matthew Cooperberg, MD, MPH
<p>In the era of prostate cancer screening, mortality rates have fallen 40 percent. The price of that has been over-diagnosis and over-treatment, something the current health care system cannot sustain. One of the major goals of Cooperberg’s research is to develop better risk assessment tools and instruments that can give the patient and doctor more confidence that the patient’s cancer will not progress.</p>
Brisk Walking May Help Men with Prostate Cancer, UCSF Study Finds
A study of 1,455 U.S. men diagnosed with early-stage prostate cancer has found a link between brisk walking and lowered risk of prostate cancer progression, according to scientists at UCSF and the Harvard School of Public Health.
UCSF Scientists Play Key Role in Success of Yervoy, a New Cancer Drug
<p>Yervoy, a new cancer drug that has been approved for the treatment of late-stage melanoma – and that is being used to treat other cancers in ongoing clinical trials – is based on a strategy for boosting the immune response developed and tested by scientists from UCSF and UC Berkeley.</p>
"Watchful waiting" has a new set of eyes
A UCSF research collaboration with GE Healthcare has produced the first results in humans of a new technology that promises to rapidly assess the presence and aggressiveness of prostate tumors in real time, by imaging the tumor’s metabolism.
Surgery better than radiation, hormone treatments for some prostate cancer, study shows
Surgery for localized prostate cancer offers a significantly higher survival rate than either external-beam radiation or hormonal therapies, according to a new study led by researchers at UCSF.
Provenge, a New Prostate Cancer Vaccine, Will Soon Be Available at UCSF
The cancer vaccine sipuleucel-T -- now commercially branded as Provenge -- will soon be available at a select group of medical centers nationwide, including UCSF.
Blocking cancer in its path: New cellular defect discovered
UCSF researchers have discovered that a key cellular defect that disturbs the production of proteins in human cells can lead to cancer susceptibility. The scientists also found that a new generation of inhibitory drugs offers promise in correcting this defect.